Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $64

Benzinga Newsdesk www.benzinga.com Negative 56.8%

Neg 56.8% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $85 to $64.